- $60.32m
- -$64.06m
- 23
- 49
- 47
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.48 | ||
| Price to Tang. Book | 0.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45.11% | ||
| Return on Equity | -33.3% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.19 | 30.98 | 15.62 | 9.16 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ikena Oncology, Inc. is a clinical-stage, targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
Directors
- Ronald Renaud NEC (52)
- Mark Manfredi PRE (50)
- Douglas Carlson COO (42)
- Alfredo Castro SVP
- Michelle Zhang SVP
- Jeffrey Ecsedy CSO (51)
- Karen McGovern VPR
- Sergio Santillana OTH (58)
- Maude Tessier OTH (43)
- David Bonita IND (45)
- Iain Dukes IND (62)
- Jean-Francois Formela IND (64)
- Otello Stampacchia IND (51)
- Richard Wooster IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 2nd, 2016
- Public Since
- March 26th, 2021
- No. of Shareholders
- 42
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 48,258,111
- Address
- 50 Northern Ave., BOSTON, 02210
- Web
- https://www.ikenaoncology.com
- Phone
- +1 8573438292
- Auditors
- Ernst & Young LLP
Upcoming Events for IKNA
Ikena Oncology Inc Annual Shareholders Meeting
Q2 2025 Ikena Oncology Inc Earnings Release
Similar to IKNA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Ikena Oncology share price?
As of Today at 21:15 UTC, shares in Ikena Oncology are trading at $1.25. This share price information is delayed by 15 minutes.
How has the Ikena Oncology share price performed this year?
Shares in Ikena Oncology last closed at $1.25 and the price had moved by -5.3% over the past 365 days. In terms of relative price strength the Ikena Oncology share price has underperformed the S&P500 Index by -14.61% over the past year.
What are the analyst and broker recommendations for Ikena Oncology?
The overall consensus recommendation for Ikena Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ikena Oncology dividend yield?
Ikena Oncology does not currently pay a dividend.
Does Ikena Oncology pay a dividend?
Ikena Oncology does not currently pay a dividend.
When does Ikena Oncology next pay dividends?
Ikena Oncology does not currently pay a dividend.
How do I buy Ikena Oncology shares?
To buy shares in Ikena Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ikena Oncology?
As of the previous close price of $1.25, shares in Ikena Oncology had a market capitalisation of $60.32m.
Where are Ikena Oncology shares listed?
Here are the trading details for Ikena Oncology:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: IKNA
What kind of share is Ikena Oncology?
Based on an overall assessment of its quality, value and momentum Ikena Oncology is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ikena Oncology share price forecast for 2025?
The analyst consensus target price for shares in Ikena Oncology is $3.00. That is 140% above the last closing price of $1.25.
Analysts covering Ikena Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$0.82 for the next financial year.
Find out moreWhat is the trend in the Ikena Oncology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ikena Oncology. Over the past six months, its share price has underperformed the S&P500 Index by -26.99%.
As of the last closing price of $1.25, shares in Ikena Oncology were trading -19.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ikena Oncology PE Ratio?
The Ikena Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ikena Oncology?
Ikena Oncology's management team is headed by:
- Ronald Renaud - NEC
- Mark Manfredi - PRE
- Douglas Carlson - COO
- Alfredo Castro - SVP
- Michelle Zhang - SVP
- Jeffrey Ecsedy - CSO
- Karen McGovern - VPR
- Sergio Santillana - OTH
- Maude Tessier - OTH
- David Bonita - IND
- Iain Dukes - IND
- Jean-Francois Formela - IND
- Otello Stampacchia - IND
- Richard Wooster - IND